Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1741 to 1755 of 7691 results

  1. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    Awaiting development [GID-TA10843] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Safeguarding adults in care homes

    Awaiting development [GID-QS10147] Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development [GID-TA10773] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development [GID-TA10867] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development [GID-TA10683] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development [GID-TA10896] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

    Awaiting development [GID-TA10916] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Bupivacaine–meloxicam for treating postoperative pain [ID2728]

    Awaiting development [GID-TA10716] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

    In development [GID-TA10311] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593

    Awaiting development [GID-TA10957] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development [GID-TA10249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477

    Awaiting development [GID-TA11271] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nitisinone for treating alkaptonuria [ID2691]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  14. Implanting a baroreceptor stimulation device for resistant hypertension

    In development [GID-IP1180] Expected publication date: TBC

    Interventional procedures guidance
    In development

  15. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development [GID-TA10657] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development